Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
NeuroFrontiersMonitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
NeuroFrontiersEngineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
Advances in MS Management: Current and Future Directions
NeuroFrontiersAdvances in MS Management: Current and Future Directions
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
NeuroFrontiersDiagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
NeuroFrontiersDuchenne Muscular Dystrophy Management: Analyzing Current Approaches
From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
NeuroFrontiersFrom Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
- 3 questions
CV Risk in Patients with Narcolepsy: See the Data
Medical Industry FeatureCV Risk in Patients with Narcolepsy: See the Data
Early Alzheimer’s Disease Treatment: Assessing Patients and Coordinating Care
Medical Industry FeatureEarly Alzheimer’s Disease Treatment: Assessing Patients and Coordinating Care
Advancements in Understanding ALS Treatment
Medical Industry FeatureAdvancements in Understanding ALS Treatment
From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice
Medical Industry FeatureFrom Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice
Investigating a gMG Therapy, Part 1: The MG-ADL Results
Medical Industry FeatureInvestigating a gMG Therapy, Part 1: The MG-ADL Results
Investigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO
Medical Industry FeatureInvestigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO
- 03/25/2025
- 03/25/2025
- 03/24/2025
- 03/24/2025
- 03/22/2025
- 03/22/2025